Branches of biology

SleepScore Labs Validates Smart Nora as an Effective Way to Reduce Snoring

Retrieved on: 
Tuesday, February 12, 2019
Women, Health, Medical devices, Mental health, Other Health, Consumer, General Health, MEN, Sleep disorders, Snoring, Branches of biology, Sleep, Neuroscience, Organ systems

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    Smart Nora is the contact-free and comfortable snoring solution that is designed to stop snoring without waking the snorer.
  • The validation study completed by SleepScore Labs found that, when snorers used Smart Nora, their partners reported that the snoring was significantly less loud and less severe.
  • Our SleepScore Labs validation study revealed that Smart Nora can help both snorers and their partners in getting better sleep as a result of decreased snoring.
  • Snoring can be a big social problem, but there isnt a one-size-fits-all solution, said Michiel Allessie, Vice President Snoring, SleepScore Labs.

Caribou Biosciences Announces Expansion of Scientific Advisory Board

Retrieved on: 
Tuesday, February 12, 2019
Health, Biotechnology, Genetics, Oncology, Pharmaceutical, Research, Science, Branches of biology, Biology, Life sciences, Genome editing, Immune system, Biotechnology, Jennifer Doudna, Reindeer, Rachel Haurwitz, CRISPR, Cas9

The newly appointed members will work with current SAB members and Caribou co-founders Jennifer Doudna, PhD and Martin Jinek, PhD.

Key Points: 
  • The newly appointed members will work with current SAB members and Caribou co-founders Jennifer Doudna, PhD and Martin Jinek, PhD.
  • The SAB will also work with Caribou management to refine Caribous emerging pipeline as well as the clinical strategy for the companys more advanced assets.
  • Additionally, Caribou offers licenses to its CRISPR-Cas9 foundational IP in multiple fields including research tools, internal research use, diagnostics, and industrial biotechnology.
  • Caribou Biosciences and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20190212005170/en/

Bicycle Therapeutics Awarded £496,000 (US $640,000) SBRI Contract to Address Antimicrobial Resistance in Humans

Retrieved on: 
Tuesday, February 12, 2019
Health, Biotechnology, Oncology, Pharmaceutical, Branches of biology, Medical specialties, Medicine, Immunology, Peripheral membrane proteins, Penicillins, Hepatotoxins, Antimicrobial resistance, Drug resistance, Penicillin, Antimicrobial, Cyclic peptide

SBRI Healthcare is an initiative to identify new ideas and technologies addressing future challenges to the U.K.s National Health Service (NHS).

Key Points: 
  • SBRI Healthcare is an initiative to identify new ideas and technologies addressing future challenges to the U.K.s National Health Service (NHS).
  • Under the contract, Bicycle will identify Bicycle inhibitors to a range of Penicillin Binding Proteins (PBPs) from pathogens of significant medical concern and investigate their antimicrobial activity.
  • Bicycles research proposal was submitted in response to a competitive call for novel strategies targeting antimicrobial resistance in humans.
  • Bicycle Therapeutics is developing a unique class of chemically synthesized medicines based on its proprietary bicyclic peptide (Bicycle) product platform to address therapeutic needs unreachable with existing treatment modalities.

EpigenCare Launches Limited Beta Release of its Personal Epigenetic Skincare Test SKINTELLI

Retrieved on: 
Tuesday, February 12, 2019
Chemistry, Physical sciences, Branches of biology, Communication design, Epigenetics, Genetic mapping, Lamarckism, Brand, Arsenic

The product is the first direct-to-consumer epigenetic test on the market to assess the dynamic qualities of a consumer's skin.

Key Points: 
  • The product is the first direct-to-consumer epigenetic test on the market to assess the dynamic qualities of a consumer's skin.
  • During this limited beta release, the SKINTELLI test will be made available first to early backers, pre-orderers, waitlisted individuals, and select invitees.
  • The company offers SKINTELLI , a direct-to-consumer epigenetics test to assess the dynamic state of one's skin quality and match it to existing skincare brands on the market.
  • EpigenCare is a winner of Johnson & Johnson's Digital Beauty Quickfire Challenge and its epigenetic technology is supported by EpiGentek Group Inc.

Designer Protein Launches Ketogenic Protein Powder

Retrieved on: 
Tuesday, February 12, 2019
Amino acids, Food and drink, Branches of biology, Cheese, Nutrition, Milk, Dietary Supplements, Whey, Leucine, Bodybuilding supplement, Protein, Egg white

Designer Keto 14G Keto Adaptogenic Protein is a natural, gluten-free protein powder that helps consumers maintain a keto lifestyle and fuel carb free bodies.

Key Points: 
  • Designer Keto 14G Keto Adaptogenic Protein is a natural, gluten-free protein powder that helps consumers maintain a keto lifestyle and fuel carb free bodies.
  • "As the Keto Diet increases in mainstream popularity we felt compelled to develop a product that could fit into this lifestyle naturally and Designer Keto was born," said Paul Pruett, CEO of Designer Protein.
  • Designer Keto has 14 grams of keto adaptogenic protein and contains rBST free muscle fueling whey and joint supporting collagen protein with the added muscle synthesis initiator, I-leucine.
  • Designer Protein was the first company to brand commercially instantize whey protein powder for the general consumer marketplace, a forerunner in promoting the removal of artificial ingredients, a pioneer of gluten-free protein powders, an advocate of kosher-certification, and the first to create a protein powder that contains the benefits of both egg yolk and egg white.

Global Multiplex Biomarker Imaging Market to Expand at 12% CAGR Till 2023

Retrieved on: 
Tuesday, February 12, 2019
Biomarkers, Branches of biology, Biology, Life sciences

A new report published by Research on Global Markets titled ' Global Multiplex Biomarker Imaging Market (2018-2023 )'studies the performance of the global multiplex biomarker imaging market over a five-year assessment period, from 2018 till 2023.

Key Points: 
  • A new report published by Research on Global Markets titled ' Global Multiplex Biomarker Imaging Market (2018-2023 )'studies the performance of the global multiplex biomarker imaging market over a five-year assessment period, from 2018 till 2023.
  • According to the report, the global multiplex biomarker imaging market is projected to expand at a compound annual growth rate (CAGR) of 12.0% during the 20182023 period, generating a revenue of USD 523.59 Mn by 2023.
  • The global multiplex biomarker imaging market is segmented based on component types, imaging techniques, applications, and end users.
  • Research on Global Markets tracks the performance of the global multiplex biomarker imaging market across the key geographies ofNorth America,Latin America,Europe,Asia-Pacific, andMiddle EastandAfrica.

Global Multiplex Biomarker Imaging Market to Expand at 12% CAGR Till 2023

Retrieved on: 
Tuesday, February 12, 2019
Biomarkers, Branches of biology, Biology, Life sciences

A new report published by Research on Global Markets titled ' Global Multiplex Biomarker Imaging Market (2018-2023 )'studies the performance of the global multiplex biomarker imaging market over a five-year assessment period, from 2018 till 2023.

Key Points: 
  • A new report published by Research on Global Markets titled ' Global Multiplex Biomarker Imaging Market (2018-2023 )'studies the performance of the global multiplex biomarker imaging market over a five-year assessment period, from 2018 till 2023.
  • According to the report, the global multiplex biomarker imaging market is projected to expand at a compound annual growth rate (CAGR) of 12.0% during the 20182023 period, generating a revenue of USD 523.59 Mn by 2023.
  • The global multiplex biomarker imaging market is segmented based on component types, imaging techniques, applications, and end users.
  • Research on Global Markets tracks the performance of the global multiplex biomarker imaging market across the key geographies ofNorth America,Latin America,Europe,Asia-Pacific, andMiddle EastandAfrica.

Neurogene Raises $68.5 Million in Series A Financing to Advance Multiple Programs in Devastating Neurological Diseases

Retrieved on: 
Tuesday, February 12, 2019
Health, Biotechnology, Clinical trials, Genetics, Pharmaceutical, Rare diseases, Neurological disorder, Medicine, Branches of biology

Neurogene, Inc ., a company founded with a mission to bring life-changing medicines to patients and families affected by rare neurological diseases, today announced a $68.5 million Series A financing.

Key Points: 
  • Neurogene, Inc ., a company founded with a mission to bring life-changing medicines to patients and families affected by rare neurological diseases, today announced a $68.5 million Series A financing.
  • Neurogene is reimagining the future for patients with rare neurological diseases and their families, said Rachel McMinn, Ph.D., Founder and Chief Executive Officer.
  • Through partnerships and our own internal expertise, we are advancing our gene therapy programs for rare neurological disorders.
  • The vast majority of rare diseases remain unaddressed, and our goal is to enable a better future for patients with these diseases.

Pen Needles Market Worth $3.4 Billion by 2023 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, February 12, 2019
Hormones, Endocrine system, Branches of biology, Medical equipment, Eli Lilly and Company, Pen needles, Insulin

CHICAGO, Feb. 12, 2019 /PRNewswire/ -- According to the new market research report "Pen Needles Marketby Type (Standard Pen Needles and Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, 10mm, 12mm), Therapy (Insulin, GLP-1, Growth Hormone, and Others), Mode of Purchase (Retail, Non-Retail) - Global Forecasts to 2023", published by MarketsandMarkets, the Pen Needles Market is expected to reach USD 3.4 billion by 2023 from an estimated USD 2.0 billion in 2018, at a CAGR of 11.0% during the forecast period (20182023).

Key Points: 
  • CHICAGO, Feb. 12, 2019 /PRNewswire/ -- According to the new market research report "Pen Needles Marketby Type (Standard Pen Needles and Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, 10mm, 12mm), Therapy (Insulin, GLP-1, Growth Hormone, and Others), Mode of Purchase (Retail, Non-Retail) - Global Forecasts to 2023", published by MarketsandMarkets, the Pen Needles Market is expected to reach USD 3.4 billion by 2023 from an estimated USD 2.0 billion in 2018, at a CAGR of 11.0% during the forecast period (20182023).
  • Growth in the Pen Needles Market is mainly driven by factors such as the growing prevalence of chronic diseases and the favorable reimbursement scenario in selected countries.
  • In 2018, the standard Pen Needles segment is expected to account for the largest share of the Pen Needles Market.
  • Growth in this market is attributed to the low cost of standard Pen Needles.

Pen Needles Market Worth $3.4 Billion by 2023 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, February 12, 2019
Hormones, Endocrine system, Branches of biology, Medical equipment, Eli Lilly and Company, Pen needles, Insulin

CHICAGO, Feb. 12, 2019 /PRNewswire/ -- According to the new market research report "Pen Needles Marketby Type (Standard Pen Needles and Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, 10mm, 12mm), Therapy (Insulin, GLP-1, Growth Hormone, and Others), Mode of Purchase (Retail, Non-Retail) - Global Forecasts to 2023", published by MarketsandMarkets, the Pen Needles Market is expected to reach USD 3.4 billion by 2023 from an estimated USD 2.0 billion in 2018, at a CAGR of 11.0% during the forecast period (20182023).

Key Points: 
  • CHICAGO, Feb. 12, 2019 /PRNewswire/ -- According to the new market research report "Pen Needles Marketby Type (Standard Pen Needles and Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, 10mm, 12mm), Therapy (Insulin, GLP-1, Growth Hormone, and Others), Mode of Purchase (Retail, Non-Retail) - Global Forecasts to 2023", published by MarketsandMarkets, the Pen Needles Market is expected to reach USD 3.4 billion by 2023 from an estimated USD 2.0 billion in 2018, at a CAGR of 11.0% during the forecast period (20182023).
  • Growth in the Pen Needles Market is mainly driven by factors such as the growing prevalence of chronic diseases and the favorable reimbursement scenario in selected countries.
  • In 2018, the standard Pen Needles segment is expected to account for the largest share of the Pen Needles Market.
  • Growth in this market is attributed to the low cost of standard Pen Needles.